한글목차

탄저병 치료제 세계 시장은 2030년까지 6억 7,160만 달러에 달할 전망

2023년에 4억 2,120만 달러로 추정되는 탄저균 치료제 세계 시장은 2023-2030년간 CAGR 6.9%로 성장하고, 2030년에는 6억 7,160만 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 항생제는 CAGR 7.1%로 성장을 지속하고, 분석 기간 종료 시 4억 2,050만 달러에 달할 것으로 예측됩니다. 면역글로불린 분절의 성장률은 분석 기간 동안 CAGR 6.7%로 추정됩니다.

미국 시장은 추정 1억 1,070만 달러, 중국은 CAGR 6.7%로 성장 예측

미국의 탄저병 치료제 시장은 2023년 1억 1,070만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 1억720만 달러 규모에 이를 것으로 예측되며 분석 기간 2023-2030년의 CAGR은 6.7%입니다. 기타 주목할만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 6.4%와 5.8%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 5.5%로 성장할 것으로 예측됩니다.

세계의 탄저병 치료제 시장 - 주요 동향과 촉진요인 요약

탄저균(Bacillus anthracis)에 의해 유발되는 탄저병은 동물과 인간 모두에 감염되는 심각한 감염입니다. 피부형, 흡입형, 소화기형의 3가지 형태가 있으며, 각각 중증도가 다릅니다. 역사적으로 탄저균은 생물 무기로 사용될 수 있었고 중요한 우려 사항이었습니다. 그 결과, 효과적인 탄저균 치료제의 개발이 공중보건과 생물방위의 양면에서 우선되어 왔습니다. 탄저균의 치료에는 시프로플록사신, 독시사이클린, 페니실린과 같은 항생제가 사용되지만 감염 초기에 투여하는 것이 가장 효과적입니다. 항생제 외에도 럭시박맙이나 탄저면역글로불린과 같은 항독소제도 개발되어 탄저균이 생산하는 독소를 중화합니다.

탄저병 치료제 분야의 진보는 지속적인 조사와 병태 생리학의 깊은 이해에 의해 추진되어 왔습니다. 최근의 동향으로는 탄저독소를 보다 효과적으로 중화하는 표적을 좁힌 새로운 항독소나 단클론항체의 개발을 들 수 있습니다. 또한, 더 적은 복용량으로 장기 면역을 얻는 것을 목표로 차세대 백신의 개발도 크게 발전하고 있습니다. 또한 나노기술을 이용한 약물전달의 연구도 진행되고 있어 기존의 치료법의 효능을 높여 부작용을 경감할 가능성이 있습니다. 이러한 기술적 진보는 특히 신속하고 효과적인 대응 메커니즘이 필수적인 바이오 테러리즘을 포함하는 시나리오에서 매우 중요합니다.

탄저병 치료제 시장의 성장은 바이오 테러 위협에 대한 인식을 높이고, 바이오 디펜스 개념에 대한 정부 자금 증가, 의료 기술 진보 등 여러 요인으로 인해 발생합니다. 제약회사에 의한 연구개발에 대한 지속적인 투자는 혁신적인 치료법과 백신의 도입 박차를 가하고 있습니다. 또한 바이오 테러 위협에 대응하는 신규 치료제에 대한 규제 당국의 지원과 승인의 가속화가 시장 성장을 가속화하고 있습니다. 정부와 보건기구에 의한 탄저병 치료제의 비축 수요도 잠재적인 아웃브레이크 대비를 보장하는 중요한 추진력이 되고 있습니다. 게다가 관민의 협력관계의 고조는 보다 효과적이고 이용하기 쉬운 탄저균 치료의 개발을 촉진하고 있습니다. 이러한 동향이 계속되고 있는 가운데, 탄저균 치료제 시장은 지속적인 기술 혁신과 공중 위생의 안전성 향상을 목표로 한 신제품의 강력한 파이프라인에 지지되어 지속적인 성장을 이루려고 하고 있다 합니다.

조사 대상 기업 예(전 86건)

• AbVacc, Inc.
• Aphios Corporation
• BlueWillow Biologics
• Crestone
• Elusys Therapeutics, Inc.
• Emergent BioSolutions, Inc.
• GC Biopharma corp.
• Hawaii Biotech, Inc.
• iNtRON Biotechnology
• Lupin Ltd.
• Paratek Pharmaceuticals
• Pfizer Inc.
• Porton Biopharma Limited
• Soligenix
• VLP Biotech;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Anthrax Therapeutics Market to Reach US$671.6 Million by 2030

The global market for Anthrax Therapeutics estimated at US$421.2 Million in the year 2023, is expected to reach US$671.6 Million by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$420.5 Million by the end of the analysis period. Growth in the Immunoglobulins segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$110.7 Million While China is Forecast to Grow at 6.7% CAGR

The Anthrax Therapeutics market in the U.S. is estimated at US$110.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$107.2 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Anthrax Therapeutics Market - Key Trends and Drivers Summarized

Anthrax, caused by the bacterium Bacillus anthracis, is a serious infectious disease that affects both animals and humans. It can manifest in three forms: cutaneous, inhalational, and gastrointestinal, each varying in severity. Historically, anthrax has been a significant concern due to its potential use as a biological weapon. As a result, the development of effective anthrax therapeutics has been a priority in both public health and biodefense. The mainstays of anthrax treatment include antibiotics such as ciprofloxacin, doxycycline, and penicillin, which are most effective when administered early in the course of infection. In addition to antibiotics, antitoxins like raxibacumab and anthrax immune globulin have been developed to neutralize the toxins produced by the bacteria, which can cause severe systemic effects.

Advancements in the field of anthrax therapeutics have been driven by ongoing research and a deeper understanding of the disease's pathophysiology. Recent innovations include the development of new antitoxins and monoclonal antibodies that offer targeted approaches to neutralize the anthrax toxins more effectively. Moreover, there has been significant progress in the creation of next-generation vaccines aimed at providing long-term immunity with fewer doses. Research is also exploring the use of nanotechnology for the targeted delivery of drugs, which could enhance the efficacy and reduce the side effects of existing treatments. These technological advancements are crucial, especially in scenarios involving bioterrorism, where rapid and effective response mechanisms are essential.

The growth in the anthrax therapeutics market is driven by several factors, including heightened awareness of bioterrorism threats, increased government funding for biodefense initiatives, and advancements in medical technology. The ongoing investment in research and development by pharmaceutical companies is spurring the introduction of innovative treatments and vaccines. Additionally, regulatory support and the fast-tracking of approvals for new therapeutics in response to bioterrorism threats are accelerating market growth. The demand for stockpiling of anthrax therapeutics by governments and health organizations is also a significant driver, ensuring preparedness for potential outbreaks. Furthermore, increasing collaborations between public and private sectors are fostering the development of more effective and accessible anthrax treatments. As these trends continue, the anthrax therapeutics market is poised for sustained growth, bolstered by continuous innovations and a robust pipeline of new products aimed at enhancing public health security.

Select Competitors (Total 86 Featured) -

• AbVacc, Inc.
• Aphios Corporation
• BlueWillow Biologics
• Crestone
• Elusys Therapeutics, Inc.
• Emergent BioSolutions, Inc.
• GC Biopharma corp.
• Hawaii Biotech, Inc.
• iNtRON Biotechnology
• Lupin Ltd.
• Paratek Pharmaceuticals
• Pfizer Inc.
• Porton Biopharma Limited
• Soligenix
• VLP Biotech;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Anthrax Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Heightened Awareness of Bioterrorism Threats Spurs Growth in Anthrax Therapeutics Market
  • Increased Government Funding for Biodefense Initiatives Expands Market Opportunity
  • Advancements in Medical Technology Propel Innovation in Anthrax Treatments
  • Demand for Stockpiling by Governments and Health Organizations Generates Steady Market Demand
  • Innovations in Antitoxins and Monoclonal Antibodies Propel Market Growth
  • Development of Next-Generation Vaccines Expands Addressable Market Opportunity
  • Use of Nanotechnology in Drug Delivery Enhances Efficacy and Reduces Side Effects
  • Economic and Geopolitical Factors Drive Investment in Biodefense Preparedness
  • Evolution of Pathogen Detection Technologies Supports Early Intervention and Treatment
  • Increased Focus on Long-Term Immunity Solutions Drives Vaccine Innovation
  • Advances in Genomic Research Generate Opportunities for Personalized Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anthrax Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Anthrax Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Anthrax Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Immunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• JAPAN
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• CHINA
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• EUROPE
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Anthrax Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Anthrax Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• FRANCE
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• GERMANY
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Rest of Europe Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Rest of Europe 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Asia-Pacific 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of World Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of World 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION